GlassScriptPhysician profile
Janet P Warner
NPI 1992706774
$2,264.89
in general payments reported to CMS, 2019-2025
26 companies · $251 in 2025
The $251 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.54 · 2020: $261 · 2021: $454 · 2022: $523 · 2023: $420 · 2024: $286 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $956.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $372.74 | 2019-2023 | Lo Loestrin Fe, Liletta |
| Organon LLC | $345.12 | 2021-2025 | Nexplanon |
| Hologic Sales and Service, LLC | $300.49 | 2019-2025 | Myosure Tissue Removal Device, Acessa Provu System, Novasure |
| Bayer Healthcare Pharmaceuticals INC. | $188.42 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $130.32 | 2023-2025 | Myfembree |
| Astellas Pharma US INC | $128.71 | 2023-2025 | Veozah, Myrbetriq |
| Therapeuticsmd, INC. | $103.21 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $95.47 | 2020-2024 | Gardasil, Gardasil 9 |
| Biogen, INC. | $84.83 | 2025 | Zurzuvae |
| Applied Medical Resources Corporation | $76.01 | 2022 | |
| Myovant Sciences INC. | $74.83 | 2021-2022 | |
| Gynesonics, INC. | $54.51 | 2023-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Millicent US INC | $50.38 | 2021-2024 | Femring, Intrarosa |
| Exeltis, USA INC. | $43.98 | 2020-2021 | |
| Agile Therapeutics, INC. | $27.95 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $25.15 | 2020-2021 | |
| Pfizer INC. | $24.85 | 2025 | |
| Daiichi Sankyo INC. | $23.66 | 2021 | |
| Medtronic, INC. | $22.48 | 2022 | |
| Convatec INC. | $17.66 | 2021 | |
| Boston Scientific Corporation | $16.61 | 2021 | |
| Baxter Healthcare | $15.68 | 2024 | Perclot |
| Avion Pharmaceuticals | $11.96 | 2022 | |
| Allergan, INC. | $11.75 | 2020 | |
| Coopersurgical, INC. | $10.85 | 2019 | |
| Mayne Pharma Commercial LLC | $7.27 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Warner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.